Immune Profiling Panel: A Proof-of-Concept Study of a New Multiplex Molecular Tool to Assess the Immune Status of Critically Ill Patients.

Autor:	Tawfik DM; EA7426 'Pathophysiology of Injury-Induced Immunosuppression,' PI3, Université Claude Bernard Lyon-1 Hospices Civils de Lyon, bioMérieux, Lyon, France.; Open Innovation and Partnerships, bioMérieux, Lyon, France., Vachot L; EA7426 'Pathophysiology of Injury-Induced Immunosuppression,' PI3, Université Claude Bernard Lyon-1 Hospices Civils de Lyon, bioMérieux, Lyon, France.; Open Innovation and Partnerships, bioMérieux, Lyon, France., Bocquet A; Open Innovation and Partnerships, bioMérieux, Lyon, France., Venet F; EA7426 'Pathophysiology of Injury-Induced Immunosuppression,' PI3, Université Claude Bernard Lyon-1 Hospices Civils de Lyon, bioMérieux, Lyon, France.; Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France., Rimmelé T; EA7426 'Pathophysiology of Injury-Induced Immunosuppression,' PI3, Université Claude Bernard Lyon-1 Hospices Civils de Lyon, bioMérieux, Lyon, France.; Anaesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France., Monneret G; EA7426 'Pathophysiology of Injury-Induced Immunosuppression,' PI3, Université Claude Bernard Lyon-1 Hospices Civils de Lyon, bioMérieux, Lyon, France.; Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France., Blein S; EA7426 'Pathophysiology of Injury-Induced Immunosuppression,' PI3, Université Claude Bernard Lyon-1 Hospices Civils de Lyon, bioMérieux, Lyon, France.; Open Innovation and Partnerships, bioMérieux, Lyon, France., Montgomery JL; BioFire Diagnostics LLC, Salt Lake City, Utah, USA., Hemmert AC; BioFire Diagnostics LLC, Salt Lake City, Utah, USA., Pachot A; EA7426 'Pathophysiology of Injury-Induced Immunosuppression,' PI3, Université Claude Bernard Lyon-1 Hospices Civils de Lyon, bioMérieux, Lyon, France.; Open Innovation and Partnerships, bioMérieux, Lyon, France., Moucadel V; EA7426 'Pathophysiology of Injury-Induced Immunosuppression,' PI3, Université Claude Bernard Lyon-1 Hospices Civils de Lyon, bioMérieux, Lyon, France.; Open Innovation and Partnerships, bioMérieux, Lyon, France., Yugueros-Marcos J; Open Innovation and Partnerships, bioMérieux, Lyon, France., Brengel-Pesce K; EA7426 'Pathophysiology of Injury-Induced Immunosuppression,' PI3, Université Claude Bernard Lyon-1 Hospices Civils de Lyon, bioMérieux, Lyon, France.; Open Innovation and Partnerships, bioMérieux, Lyon, France., Mallet F; EA7426 'Pathophysiology of Injury-Induced Immunosuppression,' PI3, Université Claude Bernard Lyon-1 Hospices Civils de Lyon, bioMérieux, Lyon, France.; Open Innovation and Partnerships, bioMérieux, Lyon, France., Textoris J; EA7426 'Pathophysiology of Injury-Induced Immunosuppression,' PI3, Université Claude Bernard Lyon-1 Hospices Civils de Lyon, bioMérieux, Lyon, France.; Open Innovation and Partnerships, bioMérieux, Lyon, France.; Anaesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2020 Jul 21; Vol. 222 (Suppl 2), pp. S84-S95.
DOI:	10.1093/infdis/jiaa248
Abstrakt:	Background: Critical illness such as sepsis is a life-threatening syndrome defined as a dysregulated host response to infection and is characterized by patients exhibiting impaired immune response. In the field of diagnosis, a gap still remains in identifying the immune profile of critically ill patients in the intensive care unit (ICU). Methods: A new multiplex immune profiling panel (IPP) prototype was assessed for its ability to semiquantify messenger RNA immune-related markers directly from blood, using the FilmArray System, in less than an hour. Samples from 30 healthy volunteers were used for the technical assessment of the IPP tool. Then the tool was clinically assessed using samples from 10 healthy volunteers and 20 septic shock patients stratified using human leukocyte antigen-DR expression on monocytes (mHLA-DR). Results: The IPP prototype consists of 16 biomarkers that target the immune response. The majority of the assays had a linear expression with different RNA inputs and a coefficient of determination (R2) > 0.8. Results from the IPP pouch were comparable to standard quantitative polymerase chain reaction and the assays were within the limits of agreement in Bland-Altman analysis. Quantification cycle values of the target genes were normalized against reference genes and confirmed to account for the different cell count and technical variability. The clinical assessment of the IPP markers demonstrated various gene modulations that could distinctly differentiate 3 profiles: healthy volunteers, intermediate mHLA-DR septic shock patients, and low mHLA-DR septic shock patients. Conclusions: The use of IPP showed great potential for the development of a fully automated, rapid, and easy-to-use immune profiling tool. The IPP tool may be used in the future to stratify critically ill patients in the ICU according to their immune status. Such stratification will enable personalized management of patients and guide treatments to avoid secondary infections and lower mortality. (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu